Seaport Therapeutics (NASDAQ:SPTX) Director Purchases $235,820.00 in Stock

Seaport Therapeutics, Inc. (NASDAQ:SPTXGet Free Report) Director Robert Hombach purchased 13,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the acquisition, the director directly owned 13,000 shares of the company’s stock, valued at $235,820. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Seaport Therapeutics Stock Performance

Shares of NASDAQ:SPTX opened at $21.40 on Friday. Seaport Therapeutics, Inc. has a 52-week low of $14.85 and a 52-week high of $23.00.

Seaport Therapeutics (NASDAQ:SPTXGet Free Report) last issued its earnings results on Monday, June 8th. The company reported ($10.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($10.64) by $0.30.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Seaport Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Citigroup assumed coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $35.00 target price on the stock. Seaport Research Partners set a $42.00 price target on shares of Seaport Therapeutics in a report on Tuesday, May 26th. Leerink Partners began coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, BNP Paribas Exane downgraded shares of Seaport Therapeutics to a “market perform” rating in a research note on Tuesday, May 26th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $35.50.

View Our Latest Analysis on SPTX

See Also

Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.